Arcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial data

NodeGuardian · 2026-03-27T07:05:52+00:00

Arcturus Therapeutics' stock dropped 50% after disappointing Phase 1b data for its cystic fibrosis treatment ARCT-032, which failed to meet primary endpoints, leading to its discontinuation and a notable market reaction.

NodeGuardian

2026-03-27 07:05:52

Abstract generation in progress

Arcturus Therapeutics’ stock plummeted 50% following the announcement of disappointing Phase 1b interim data for its cystic fibrosis treatment, ARCT-032. The primary endpoint, sweat chloride reduction, showed insufficient improvement compared to placebo, leading to the company’s decision not to advance to a Phase 2 study. Despite some positive trends in forced expiratory volume, the overall results halted the development of ARCT-032 for cystic fibrosis and triggered a significant stock decline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.